<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-37541" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Ampicillin/Sulbactam</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Peechakara</surname>
            <given-names>Basil V.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gupta</surname>
            <given-names>Mohit</given-names>
          </name>
          <aff>Cleveland Clinic Foundation</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Basil Peechakara declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mohit Gupta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>11</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-37541.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">The ampicillin/sulbactam combination demonstrates synergy in addressing bacterial strains resistant to ampicillin, thus providing broader coverage. This drug combination incorporates a &#x003b2;-lactamase inhibitor into ampicillin, extending coverage against potentially resistant bacteria. The ampicillin/sulbactam combination has been approved by the U.S. Food and Drug Administration (FDA) for treating&#x000a0;skin and skin structure infections, intra-abdominal infections, and gynecological infections. This activity emphasizes the appropriate use of ampicillin/sulbactam by providing information on its indications, mechanism of action, adverse events, and drug interactions, which is crucial for the interprofessional healthcare team to ensure the delivery of optimal patient care.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the appropriate indications for ampicillin/sulbactam combination therapy, considering bacterial resistance patterns and the spectrum of coverage.</p></list-item><list-item><p>Assess patient responses and monitor for adverse events during ampicillin/sulbactam therapy by adjusting treatment as needed.</p></list-item><list-item><p>Apply knowledge of the mechanism of action and pharmacokinetics of ampicillin/sulbactam in clinical decision-making for optimal patient care.</p></list-item><list-item><p>Collaborate with pharmacists, infectious disease specialists, and other&#x000a0;interprofessional healthcare professionals for a coordinated approach to ampicillin/sulbactam therapy, contribute to antimicrobial stewardship efforts, and address antibiotic resistance concerns.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=37541&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=37541">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-37541.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Ampicillin is a &#x003b2;-lactam antimicrobial,&#x000a0;whereas&#x000a0;sulbactam is a &#x003b2;-lactamase inhibitor. The combination of ampicillin and sulbactam demonstrates synergy in addressing bacterial strains resistant to ampicillin, thus providing broader coverage.<xref ref-type="bibr" rid="article-37541.r1">[1]</xref>&#x000a0;Bacteria susceptible to ampicillin/sulbactam include&#x000a0;<italic toggle="yes">Haemophilus&#x000a0;</italic><italic toggle="yes">influenzae</italic>,&#x000a0;<italic toggle="yes">Escherichia coli</italic>,&#x000a0;<italic toggle="yes">Acinetobacter</italic>, <italic toggle="yes">Klebsiella</italic>,<italic toggle="yes"> Staphylococcus aureus</italic>,&#x000a0;<italic toggle="yes">Enterobacter</italic>, and anaerobes.&#x000a0;This drug combination incorporates a &#x003b2;-lactamase inhibitor into ampicillin, extending coverage against potentially resistant bacteria.&#x000a0;</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>The U.S. Food and Drug Administration (FDA) has approved the combination of ampicillin and sulbactam to treat the conditions below that are caused by susceptible bacteria.&#x000a0;</p>
        <p><bold>Skin and skin structure infections:</bold>&#x000a0;The ampicillin/sulbactam combination&#x000a0;demonstrates efficacy comparable to third-generation cephalosporins in treating skin infections, whether in patients with or without a history of intravenous (IV) drug abuse.<xref ref-type="bibr" rid="article-37541.r2">[2]</xref></p>
        <p><bold>Intra-abdominal infections:</bold>&#x000a0;The ampicillin/sulbactam combination is recommended for mild to moderate community-acquired intra-abdominal infections. However, in cases of more severe infections that demand broader coverage against facultative and gram-negative aerobic bacteria, the use of combination antimicrobials, such as carbapenem in conjunction with vancomycin, may be necessary.<xref ref-type="bibr" rid="article-37541.r3">[3]</xref></p>
        <p><bold>Gynecological infections:</bold> Pelvic inflammatory disease arises from sexually transmitted organisms (<italic toggle="yes">Neisseria gonorrhoeae</italic> or <italic toggle="yes">Chlamydia trachomatis</italic>) or anaerobic vaginal flora. First-line treatment typically involves cefoxitin or cefotetan with doxycycline or clindamycin with gentamicin plus doxycycline. The ampicillin/sulbactam combination demonstrates comparable efficacy and is a crucial alternative regimen for gynecological infections.<xref ref-type="bibr" rid="article-37541.r4">[4]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p><bold>Lower respiratory tract infections:</bold>&#x000a0;In the treatment of lower respiratory tract infections, ampicillin/sulbactam exhibits higher efficacy compared to various third-generation cephalosporins (cefuroxime and cefotaxime), second-generation cephalosporin (cefoxitin), mezlocillin, and imipenem/cilastatin. Although the difference is not clinically significant, it suggests a favorable performance of ampicillin/sulbactam.<xref ref-type="bibr" rid="article-37541.r5">[5]</xref><xref ref-type="bibr" rid="article-37541.r6">[6]</xref><xref ref-type="bibr" rid="article-37541.r7">[7]</xref></p>
        <p><bold>Aspiration pneumonia:</bold>&#x000a0;In a study by Kadowaki et al, the efficacy of ampicillin/sulbactam, clindamycin, and imipenem/cilastatin was compared. Cure rates for ampicillin/sulbactam were found to be comparable to those of imipenem/cilastatin despite clindamycin being the least expensive option.<xref ref-type="bibr" rid="article-37541.r8">[8]</xref></p>
        <p><bold>Diabetic foot infections:</bold>&#x000a0;Ampicillin/sulbactam demonstrates comparable effectiveness to imipenem/cilastatin <xref ref-type="bibr" rid="article-37541.r9">[9]</xref>&#x000a0;and piperacillin/tazobactam, which are comparably effective. However, piperacillin/tazobactam has broader coverage, and the most common gram-negative bacterium isolated was&#x000a0;<italic toggle="yes">Pseudomonas aeruginosa</italic>.</p>
        <p><bold>Pediatric infections:</bold>&#x000a0;In the pediatric population, ampicillin/sulbactam is indicated for conditions such as epiglottitis, periorbital infections, acute fulminant meningococcemia, and sepsis management.<xref ref-type="bibr" rid="article-37541.r10">[10]</xref></p>
        <p><bold>Infection in the intensive care unit (ICU) with&#x000a0;</bold><italic toggle="yes"><bold>Acinetobacter baumannii</bold></italic><bold>:</bold> Ampicillin/sulbactam is proven to be effective and safe for use in multidrug-resistant&#x000a0;<italic toggle="yes">A baumannii</italic>&#x000a0;infections.<xref ref-type="bibr" rid="article-37541.r11">[11]</xref></p>
        <p><bold>Endocarditis:</bold> Ampicillin can be combined with aminoglycosides to treat infections caused by susceptible strains of <italic toggle="yes">Enterococcus.</italic><xref ref-type="bibr" rid="article-37541.r12">[12]</xref></p>
        <p><bold>Osteonecrosis of the jaw (ONJ):</bold>&#x000a0;Ampicillin/sulbactam has demonstrated effectiveness against ONJ caused by <italic toggle="yes">Streptococcus</italic>&#x000a0;and <italic toggle="yes">Staphylococcus</italic>, primarily found within the biofilm of ONJ.<xref ref-type="bibr" rid="article-37541.r13">[13]</xref></p>
        <p>The literature review indicates that ampicillin/sulbactam may be beneficial in managing infectious pulmonary artery pseudoaneurysms.<xref ref-type="bibr" rid="article-37541.r14">[14]</xref></p>
      </sec>
      <sec id="article-37541.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Ampicillin is a &#x003b2;-lactam antimicrobial, whereas sulbactam is a &#x003b2;-lactamase inhibitor.</p>
        <p>
<bold>Mechanism of Ampicillin</bold>
</p>
        <p>Similar to other &#x003b2;-lactam antimicrobials, the mode of action of ampicillin on susceptible organisms can be considered a 2-step process. In the initial step, the drug binds to primary receptors known as membrane-bound penicillin-binding proteins (PBPs). These proteins play crucial roles in the cell cycle&#x02013;related morphogenetic formation of the cell wall peptidoglycan. Consequently, the inactivation of PBPs by bound antimicrobials immediately arrests their function.</p>
        <p>The second stage involves the physiological effects resulting from this receptor-ligand interaction. PBPs&#x000a0;are involved in the late stages of peptidoglycan synthesis in the cell wall. As peptidoglycan is crucial for maintaining the integrity of the cell wall, any disruption leads to lysis and eventual cell death, especially in the context of the hypotonic environment in which the cell resides.<xref ref-type="bibr" rid="article-37541.r15">[15]</xref></p>
        <p>
<bold>Mechanism of Sulbactam</bold>
</p>
        <p>The production of &#x003b2;-lactamase is critically essential for the evolution of drug-resistant bacteria. Combinations of &#x003b2;-lactams with &#x003b2;-lactamase inhibitors, such as ampicillin/sulbactam, broaden the spectrum of &#x003b2;-lactams by inhibiting their hydrolysis by &#x003b2;-lactamases.<xref ref-type="bibr" rid="article-37541.r16">[16]</xref></p>
        <p>
<bold>Mechanism of Resistance</bold>
</p>
        <p>A study demonstrated that in <italic toggle="yes">A&#x000a0;baumannii</italic>, strains with PBP-3 mutations exhibited elevated levels of resistance to sulbactam. Conversely, strains with mutations in cell wall metabolism or stress response genes displayed lower resistance to sulbactam.<xref ref-type="bibr" rid="article-37541.r17">[17]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;Peak serum concentrations of ampicillin and sulbactam are reached following a 15-minute IV infusion. The steady-state volumes of distribution range from 14.2 to 15.1 L for ampicillin and 12.2 to 16.3&#x02009;L for sulbactam. The penetration of ampicillin and sulbactam into the cerebrospinal fluid (CSF) is enhanced in the presence of inflamed meninges.<xref ref-type="bibr" rid="article-37541.r18">[18]</xref></p>
        <p><bold>Distribution:</bold> Ampicillin and sulbactam exhibit extensive distribution in extracellular fluids and tissues. Approximately 28% of ampicillin is reversibly bound to human serum proteins, whereas sulbactam has approximately 38% plasma protein binding. The steady-state volumes of distribution range from 14.2 to 15.1 L for ampicillin and 12.2 to 16.3 L for sulbactam.</p>
        <p><bold>Metabolism:</bold>&#x000a0;Ampicillin undergoes metabolism by penicillinase, leading to the formation of penicilloic acid and other metabolites.<xref ref-type="bibr" rid="article-37541.r19">[19]</xref></p>
        <p><bold>Elimination:</bold>&#x000a0;Ampicillin and sulbactam are primarily excreted&#x000a0;in urine via glomerular filtration and tubular excretion. The half-life of ampicillin and sulbactam is approximately 1 hour in healthy subjects.<xref ref-type="bibr" rid="article-37541.r20">[20]</xref></p>
      </sec>
      <sec id="article-37541.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Ampicillin/sulbactam is not absorbed adequately after oral absorption. In IV formulations, penetration into tissues and fluids includes intraperitoneal fluid (60%), myometrium (64%), sputum (12% to 14%), and CSF (11% to 14%).</p>
        <p>
<bold>Adult Dosage and Administration</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Ampicillin/sulbactam administration can be administered via intramuscular (IM) or IV routes.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>For IV administration, healthcare providers should administer the dose by slow IV injection over at least 10 to 15 minutes.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Administer ampicillin/sulbactam by deep intramuscular injection within 1 hour of preparation.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The recommended adult dosage of ampicillin/sulbactam is 1.5 g (1 g ampicillin + 0.5 g sulbactam) to 3 g (2 g ampicillin + 1 g sulbactam) every 6 hours. The total dosage of sulbactam should not exceed 4 g/d.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The 2022 guidelines from the Infectious Diseases Society of America (IDSA) recommend ampicillin/sulbactam at a dosage of 9 g IV administered q8h over 4 hours infusion for infections caused by carbapenem-resistant <italic toggle="yes">A baumannii</italic> (CRAB). In cases of mild infections caused by CRAB organisms sensitive to ampicillin/sulbactam, a recommended dosage is 3 g IV every q4h.<xref ref-type="bibr" rid="article-37541.r21">[21]</xref>&#x000a0;Notably, even in cases where CRAB strains show nonsusceptibility to ampicillin/sulbactam, this combination may still be a viable treatment option due to the potential for sulbactam to saturate altered&#x000a0;PBP targets.&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment: </bold>No dosage&#x000a0;adjustment is suggested.</p>
        <p><bold>Renal impairment:</bold> The excretion of ampicillin/sulbactam is primarily through the renal route, resulting in an increased half-life in patients with impaired renal function.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>If creatine clearance exceeds 30 mL/min, the recommended dosage of ampicillin/sulbactam is 1.5&#x000a0;to 3 g administered every 6 hours, and no dosage adjustment is necessary.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>If the creatine clearance is between 15 and 29 mL/min, the recommended dosage of ampicillin/sulbactam is 1.5&#x000a0;to 3 g administered every 12 hours.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>If the creatine clearance is between 15 and 29 mL/min, the recommended dosage of ampicillin/sulbactam is 1.5&#x000a0;to 3 g daily.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Ampicillin and sulbactam elimination kinetics are similarly affected in patients with impaired renal function. Therefore, the ratio of one to the other will remain constant at a given level of renal function.<xref ref-type="bibr" rid="article-37541.r22">[22]</xref></p>
          </list-item>
        </list>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>The American College of Obstetricians and Gynecologists (ACOG) recommends the use of IV ampicillin and erythromycin for patients with preterm pre-labor rupture of membranes less than 34 weeks of gestation to prevent group B streptococcal perinatal infection.<xref ref-type="bibr" rid="article-37541.r23">[23]</xref></p>
        <p><bold>Breastfeeding considerations: </bold>Clinical data suggest that ampicillin/sulbactam&#x000a0;is present in low levels in breast milk, which are not expected to cause adverse effects in breastfed infants. However, the disruption of the infant's gastrointestinal flora can result&#x000a0;in diarrhea or thrush. Overall, ampicillin/sulbactam is acceptable for use by nursing mothers.<xref ref-type="bibr" rid="article-37541.r24">[24]</xref></p>
        <p><bold>Pediatric patients:</bold>&#x000a0;In pediatric patients, administering ampicillin/sulbactam involves tailored dosing based on age and body weight, with specific considerations for neonates and premature infants.</p>
        <list list-type="bullet">
          <list-item>
            <p>For children aged 1 year or older: The recommended daily dosage of ampicillin/sulbactam in pediatric patients is 300 mg/kg of body weight administered via IV infusion in equally divided doses every 6 hours. Caution must be exercised when&#x000a0;administering ampicillin/sulbactam to neonates&#x000a0;younger&#x000a0;than 1 week and premature infants due to their underdeveloped urinary system.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Dosage recommendations for pediatric patients with a body weight of 40 kg or more align with those for adult patients.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The duration of IV therapy should not routinely exceed 14 days.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The pharmacokinetics of ampicillin/sulbactam remain consistent in the pediatric population compared to adults.<xref ref-type="bibr" rid="article-37541.r25">[25]</xref></p>
          </list-item>
        </list>
        <p><bold>Older patients: </bold>The product labeling lacks specific dosage recommendations for using ampicillin/sulbactam in older individuals. Therefore, dosing should be determined based on renal function.</p>
      </sec>
      <sec id="article-37541.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Adverse Reactions</bold>
</p>
        <p><bold>Local adverse reactions:</bold> These reactions may include pain at the IM or IV injection site and thrombophlebitis.</p>
        <p><bold>Gastrointestinal adverse drug reactions:&#x000a0;</bold>These drug reactions may include stomatitis, nausea and vomiting, pseudomembranous colitis, enterocolitis, and black hairy tongue.<xref ref-type="bibr" rid="article-37541.r26">[26]</xref></p>
        <p><bold>Hypersensitivity reactions:</bold>&#x000a0;These&#x000a0;reactions may manifest as frequent reports of skin rashes and urticaria. Additionally, there are documented cases of erythema multiforme and exfoliative dermatitis. The most severe complication is anaphylaxis, primarily associated with the parenteral form, necessitating prompt treatment.<xref ref-type="bibr" rid="article-37541.r27">[27]</xref></p>
        <p><bold>Hepatotoxicity:&#x000a0;</bold>Hepatotoxicity may involve a moderate elevation of serum glutamic oxaloacetic transaminase (SGOT), commonly observed in infants, with its significance remaining unknown. Furthermore, mild and transient elevations have been noted with repeated intramuscular administration in individuals receiving larger-than-usual doses.</p>
        <p>Evidence indicates that SGOT or aspartate aminotransferase is released at the intramuscular injection site, and the increased quantities observed in the blood may not necessarily originate from the liver as a source.<xref ref-type="bibr" rid="article-37541.r28">[28]</xref></p>
        <p><bold>Hemato-lymphatic system reactions:&#x000a0;</bold>These reactions are attributed to a hypersensitive phenomenon and are generally reversible upon discontinuation of therapy. These reactions may include hemolytic anemia, thrombocytopenia, eosinophilia, thrombocytopenic purpura, and agranulocytosis.<xref ref-type="bibr" rid="article-37541.r29">[29]</xref></p>
        <p><bold>Neurological adverse drug reactions:&#x000a0;</bold>These reactions may include headaches&#x000a0;and seizures.<xref ref-type="bibr" rid="article-37541.r30">[30]</xref></p>
        <p><bold>Opportunistic infections:&#x000a0;</bold>These infections may manifest as superinfection with <italic toggle="yes">Clostridium difficile&#x02013;</italic>associated diarrhea (CDAD) and fungal infections. In such cases, discontinuation of therapy and substitution with appropriate alternative treatment are warranted.<xref ref-type="bibr" rid="article-37541.r31">[31]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The administration of the cholera vaccine is not recommended during systemic antibiotic treatment, as it can reduce its efficacy. Prolonged antibiotic treatment with intravesical BCG adversely impacts bladder cancer disease recurrence and outcomes. Simultaneous use should be avoided.<xref ref-type="bibr" rid="article-37541.r32">[32]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The concurrent use of allopurinol with ampicillin increases the risk of Stevens-Johnson syndrome.<xref ref-type="bibr" rid="article-37541.r33">[33]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Ampicillin is a bactericidal drug, and combining bactericidal drugs with bacteriostatic drugs, such as doxycycline, is generally not recommended.<xref ref-type="bibr" rid="article-37541.r34">[34]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-37541.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Hypersensitivity</bold>
</p>
        <p>Reports exist of severe and life-threatening anaphylactoid reactions with ampicillin/sulbactam therapy. Although anaphylaxis is more common following parenteral therapy, it can also occur after oral administration. In addition, anaphylaxis is more likely in a patient with a previous history of penicillin hypersensitivity and/or reaction to multiple allergens. Therefore, a thorough inquiry is essential before initiating therapy concerning hypersensitivity reactions to cephalosporins, allergens, or penicillin.</p>
        <p>In the event of a hypersensitivity reaction, clinicians should promptly discontinue therapy and initiate alternative treatment. Anaphylactoid reactions necessitate immediate emergency treatment with oxygen, epinephrine, steroids, and airway management, including intubation if indicated.</p>
        <p>
<bold><italic toggle="yes">Clostridioides difficile</italic>&#x000a0;Infection</bold>
</p>
        <p>Antibacterial treatment disrupts the natural flora of the intestine, leading to the overgrowth of<italic toggle="yes"> C difficile</italic>. CDAD occurs when using nearly all antibacterial agents, especially ampicillin. The resulting severity of CDAD may range from mild diarrhea to fulminant colitis. Hypertoxin-producing <italic toggle="yes">C difficile</italic> strains cause increased morbidity and mortality, as these strains are refractory to the recommended antimicrobial therapy and may require colectomy. Therefore,&#x000a0;CDAD&#x000a0;may be a consideration for all patients with diarrhea after antibacterial use. Therefore, CDAD should be considered for all patients with diarrhea after antibacterial use. A thorough medical history is essential in these cases because it&#x000a0;may reportedly occur over 2 months after administering antibacterial agents.</p>
        <p>If CDAD is confirmed, discontinuing ongoing antimicrobial therapy not directed against the organism may be necessary. Considerations should include adequate fluid and electrolyte management, protein supplementation, the appropriate antimicrobial regimen for <italic toggle="yes">C difficile</italic>, and surgical evaluation if indicated.<xref ref-type="bibr" rid="article-37541.r35">[35]</xref></p>
        <p>
<bold>Concomitant Infectious Mononucleosis Infection</bold>
</p>
        <p>Many patients diagnosed with infectious mononucleosis and initiated on ampicillin/sulbactam therapy develop a rash. Ideally, the rash manifests 7 to 10 days after initiating ampicillin/sulbactam therapy and persists for a few days to one week after discontinuing the drug. In most cases, the rash is maculopapular, generalized, and pruritic. Therefore, the administration of ampicillin/sulbactam is not recommended in these patients. The actual allergic status of these patients to penicillin remains unknown.<xref ref-type="bibr" rid="article-37541.r36">[36]</xref></p>
        <p>
<bold>Hepatic Dysfunction</bold>
</p>
        <p>As reexposure to ampicillin can result in the recurrence of drug-induced liver injury (DILI), it is advised to avoid ampicillin use in patients with a history of aminopenicillin-induced hepatitis.<xref ref-type="bibr" rid="article-37541.r29">[29]</xref></p>
      </sec>
      <sec id="article-37541.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>During prolonged therapy, it is advisable to monitor renal, hepatic, and hematologic parameters periodically. In addition, monitoring for signs of anaphylaxis should be maintained, particularly during the first dose.<xref ref-type="bibr" rid="article-37541.r37">[37]</xref></p>
        <p>A recent observational cohort study involving 150 patients (intervention: <italic toggle="yes">n</italic>=75; control: <italic toggle="yes">n</italic>=75) investigated DILI caused by ampicillin/sulbactam. The study explored the correlation between DILI and the albumin-bilirubin (ALBI) score, which indicates hepatic functional reserve. Results revealed a 9.5% incidence of DILI, notably showing that patients with a baseline ALBI score of &#x02265;-2.00 had a significantly elevated risk for ampicillin/sulbactam&#x02013;induced DILI. The ALBI score emerged as a valuable predictor of DILI in patients undergoing ABPC/SBT therapy, emphasizing its clinical relevance for therapeutic monitoring.<xref ref-type="bibr" rid="article-37541.r38">[38]</xref></p>
      </sec>
      <sec id="article-37541.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>Patients with impaired renal function face an elevated risk of overdose due to decreased clearance. Neurological adverse reactions, such as convulsions, may occur when high CSF levels of ampicillin are reached.</p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>In cases of overdose, it is imperative to discontinue ampicillin/sulbactam, provide symptomatic treatment, and offer supportive care. In severe overdoses, hemodialysis should be initiated to remove ampicillin from circulation, considering that the molecular weight and degree of protein binding of sulbactam are compatible with hemodialysis.<xref ref-type="bibr" rid="article-37541.r39">[39]</xref><xref ref-type="bibr" rid="article-37541.r40">[40]</xref>&#x000a0;Corticosteroids&#x000a0;can manage&#x000a0;the allergic manifestations of immunoallergic hepatitis due to ampicillin.<xref ref-type="bibr" rid="article-37541.r29">[29]</xref><bold>&#x000a0;</bold></p>
        <p>In a recent&#x000a0;study investigating DILI caused by ampicillin/sulbactam, researchers examined the correlation between DILI and the ALBI score&#x02014;an indicator of hepatic functional reserve. The study, including 380 patients, revealed an incidence of DILI at 9.5%. The results of Cox regression analysis demonstrated a significantly increased risk of ampicillin/sulbactam&#x02013;induced DILI in patients with a baseline ALBI score of &#x02265;-2.00. Therefore, the ALBI score emerges as a practical and valuable tool for predicting the likelihood of DILI attributed to ampicillin/sulbactam, especially in patients with an ALBI score &#x02265;-2.00. This underscores the need for vigilant and routine liver function monitoring in these individuals.<xref ref-type="bibr" rid="article-37541.r38">[38]</xref></p>
      </sec>
      <sec id="article-37541.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Ampicillin/sulbactam is extensively prescribed by primary care providers, nurse practitioners, internists, surgeons, and other healthcare professionals. Despite its efficacy, clinicians should avoid empirical prescriptions for all infections due to the increasing global resistance to this agent. Hence, healthcare professionals should initiate this medication only for specific indications, ensuring the appropriate duration of drug use. Antimicrobial stewardship is a coordinated program designed to promote the proper use of antimicrobials. Studies indicate that implementing antimicrobial stewardship programs effectively reduces antimicrobial resistance and mitigates the spread of infections caused by multidrug-resistant organisms.<xref ref-type="bibr" rid="article-37541.r41">[41]</xref></p>
        <p>Pharmacists are critical in medication management by verifying dosing, assessing the appropriateness of selecting ampicillin/sulbactam based on infection type and available antibiogram data, counseling patients on medication administration, and evaluating potential drug-drug interactions.</p>
        <p>In many instances, nurses are responsible for administering drugs in the hospital setting, monitoring for adverse events, providing patient counseling, liaising&#x000a0;with all interprofessional team members, and assessing therapeutic effectiveness. The nursing staff communicates their observations to the clinician to facilitate ongoing treatment adjustments. In the case of an overdose, emergency department physicians and nurses should rapidly stabilize the patient.</p>
        <p>Nephrology consultation is essential for extracorporeal removal in severe overdose cases.&#x000a0;A psychiatrist consultation is necessary if the overdose is intentional. Infectious disease consultation is vital for superinfections. Gastroenterology consultation is crucial for colitis and toxic megacolon. A psychiatrist consultation is required if the overdose is intentional. Consultation with infectious disease specialists is vital for addressing superinfections, while gastroenterology consultation is crucial for managing colitis and toxic megacolon.<xref ref-type="bibr" rid="article-37541.r42">[42]</xref> Clinical pharmacists play a significant role in preventing drug-induced complications, such as acute kidney injury, showcasing their crucial impact on patient care.</p>
        <p>Clinical pharmacists contribute significantly to therapeutic outcomes by providing expert recommendations on drug selection, administration, dosage adjustments, and monitoring for potential interactions or adverse effects. In addition, these observational findings emphasize the crucial role of ampicillin&#x02014;a commonly used antibiotic in inpatient care. The involvement of a clinical pharmacist can significantly reduce the incidence of acute kidney injury related to medications such as ampicillin, highlighting the vital contribution of pharmacists in enhancing overall patient safety and well-being in critical care settings.<xref ref-type="bibr" rid="article-37541.r43">[43]</xref></p>
        <p>Multiple healthcare providers may be involved in caring for patients requiring ampicillin therapy, including physicians, specialists, pharmacists, and nurses. In such a scenario, the team should collaborate closely to&#x000a0;maximize&#x000a0;efficacy and minimize adverse drug reactions. Open communication lines between all healthcare team members are essential to the interprofessional model. In summary, an interprofessional team approach optimizes patient outcomes related to ampicillin/sulbactam therapy.</p>
      </sec>
      <sec id="article-37541.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=37541&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=37541">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/37541/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=37541">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-37541.s11">
        <title>References</title>
        <ref id="article-37541.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gonz&#x000e1;lez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Urrea</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>del Solar</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bello</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zemelman</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>[A combination of ampicillin and sulbactam: effect on aerobic and anaerobic gram-negative bacteria].</article-title>
            <source>Rev Med Chil</source>
            <year>1990</year>
            <month>May</month>
            <volume>118</volume>
            <issue>5</issue>
            <fpage>548</fpage>
            <page-range>548-54</page-range>
            <pub-id pub-id-type="pmid">2293275</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Talan</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Summanen</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Finegold</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Ampicillin/sulbactam and cefoxitin in the treatment of cutaneous and other soft-tissue abscesses in patients with or without histories of injection drug abuse.</article-title>
            <source>Clin Infect Dis</source>
            <year>2000</year>
            <month>Aug</month>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>464</fpage>
            <page-range>464-71</page-range>
            <pub-id pub-id-type="pmid">10987706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Solomkin</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Mazuski</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Baron</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Sawyer</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Nathens</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>DiPiro</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Buchman</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dellinger</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Jernigan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gorbach</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chow</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Bartlett</surname>
                <given-names>J</given-names>
              </name>
              <collab>Infectious Diseases Society of America</collab>
            </person-group>
            <article-title>Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections.</article-title>
            <source>Clin Infect Dis</source>
            <year>2003</year>
            <month>Oct</month>
            <day>15</day>
            <volume>37</volume>
            <issue>8</issue>
            <fpage>997</fpage>
            <page-range>997-1005</page-range>
            <pub-id pub-id-type="pmid">14523762</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McKinnon</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Neuhauser</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and cost of ampicillin-sulbactam and ticarcillin-clavulanate in the treatment of hospitalized patients with bacterial infections.</article-title>
            <source>Pharmacotherapy</source>
            <year>1999</year>
            <month>Jun</month>
            <volume>19</volume>
            <issue>6</issue>
            <fpage>724</fpage>
            <page-range>724-33</page-range>
            <pub-id pub-id-type="pmid">10391418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Geckler</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>A comparison of ampicillin/sulbactam and cefuroxime in the treatment of patients with bacterial infections of the lower respiratory tract.</article-title>
            <source>Clin Ther</source>
            <year>1994</year>
            <season>Jul-Aug</season>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>662</fpage>
            <page-range>662-72</page-range>
            <pub-id pub-id-type="pmid">7982254</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jauregui</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Minns</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hageage</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>A comparison of ampicillin/sulbactam versus cefotaxime in the therapy of lower respiratory tract infections in hospitalized patients.</article-title>
            <source>J Chemother</source>
            <year>1995</year>
            <month>Apr</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>153</fpage>
            <page-range>153-6</page-range>
            <pub-id pub-id-type="pmid">7666123</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yanagihara</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fukuda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Seki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Izumikawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Higashiyama</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Miyazaki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hirakata</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tomono</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mizuta</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tsukamoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kohno</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Clinical comparative study of sulbactam/ampicillin and imipenem/cilastatin in elderly patients with community-acquired pneumonia.</article-title>
            <source>Intern Med</source>
            <year>2006</year>
            <volume>45</volume>
            <issue>17</issue>
            <fpage>995</fpage>
            <page-range>995-9</page-range>
            <pub-id pub-id-type="pmid">17015999</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kadowaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Demura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mizuno</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Uesaka</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ameshima</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Miyamori</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ishizaki</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Reappraisal of clindamycin IV monotherapy for treatment of mild-to-moderate aspiration pneumonia in elderly patients.</article-title>
            <source>Chest</source>
            <year>2005</year>
            <month>Apr</month>
            <volume>127</volume>
            <issue>4</issue>
            <fpage>1276</fpage>
            <page-range>1276-82</page-range>
            <pub-id pub-id-type="pmid">15821205</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grayson</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Gibbons</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Habershaw</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Pomposelli</surname>
                <given-names>FB</given-names>
              </name>
              <name>
                <surname>Rosenblum</surname>
                <given-names>BI</given-names>
              </name>
              <name>
                <surname>Levin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Karchmer</surname>
                <given-names>AW</given-names>
              </name>
            </person-group>
            <article-title>Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients.</article-title>
            <source>Clin Infect Dis</source>
            <year>1994</year>
            <month>May</month>
            <volume>18</volume>
            <issue>5</issue>
            <fpage>683</fpage>
            <page-range>683-93</page-range>
            <pub-id pub-id-type="pmid">8075257</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kanra</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Se&#x000e7;meer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>G&#x000f6;n&#x000e7;</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Ceyhan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ecevit</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Periorbital cellulitis: a comparison of different treatment regimens.</article-title>
            <source>Acta Paediatr Jpn</source>
            <year>1996</year>
            <month>Aug</month>
            <volume>38</volume>
            <issue>4</issue>
            <fpage>339</fpage>
            <page-range>339-42</page-range>
            <pub-id pub-id-type="pmid">8840541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jellison</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Mckinnon</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Rybak</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam.</article-title>
            <source>Pharmacotherapy</source>
            <year>2001</year>
            <month>Feb</month>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>142</fpage>
            <page-range>142-8</page-range>
            <pub-id pub-id-type="pmid">11213849</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baddour</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Bayer</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Fowler</surname>
                <given-names>VG</given-names>
              </name>
              <name>
                <surname>Tleyjeh</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Rybak</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Barsic</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lockhart</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Gewitz</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Levison</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Bolger</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Steckelberg</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Baltimore</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Fink</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>O'Gara</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Taubert</surname>
                <given-names>KA</given-names>
              </name>
              <collab>American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council</collab>
            </person-group>
            <article-title>Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association.</article-title>
            <source>Circulation</source>
            <year>2015</year>
            <month>Oct</month>
            <day>13</day>
            <volume>132</volume>
            <issue>15</issue>
            <fpage>1435</fpage>
            <page-range>1435-86</page-range>
            <pub-id pub-id-type="pmid">26373316</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Straub</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stapf</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vollmer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Linz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>L&#x000e2;m</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>K&#x000fc;bler</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brands</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Scherf-Clavel</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Hartmann</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Bone Concentration of Ampicillin/Sulbactam: A Pilot Study in Patients with Osteonecrosis of the Jaw.</article-title>
            <source>Int J Environ Res Public Health</source>
            <year>2022</year>
            <month>Nov</month>
            <day>13</day>
            <volume>19</volume>
            <issue>22</issue>
            <pub-id pub-id-type="pmid">36429636</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nakayama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yamaguchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Iikura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Izumi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Takeda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hojo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sugiyama</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Infectious Pulmonary Artery Pseudoaneurysm That Resolved with Conservative Treatment.</article-title>
            <source>Intern Med</source>
            <year>2022</year>
            <month>Oct</month>
            <day>15</day>
            <volume>61</volume>
            <issue>20</issue>
            <fpage>3089</fpage>
            <page-range>3089-3093</page-range>
            <pub-id pub-id-type="pmid">35283388</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghooi</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Thatte</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Inhibition of cell wall synthesis--is this the mechanism of action of penicillins?</article-title>
            <source>Med Hypotheses</source>
            <year>1995</year>
            <month>Feb</month>
            <volume>44</volume>
            <issue>2</issue>
            <fpage>127</fpage>
            <page-range>127-31</page-range>
            <pub-id pub-id-type="pmid">7596307</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crass</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Pai</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and Pharmacodynamics of &#x003b2;-Lactamase Inhibitors.</article-title>
            <source>Pharmacotherapy</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>39</volume>
            <issue>2</issue>
            <fpage>182</fpage>
            <page-range>182-195</page-range>
            <pub-id pub-id-type="pmid">30589457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Penwell</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Giacobbe</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Gu</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Thresher</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McLaughlin</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Huband</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>DeJonge</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Ehmann</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>59</volume>
            <issue>3</issue>
            <fpage>1680</fpage>
            <page-range>1680-9</page-range>
            <pub-id pub-id-type="pmid">25561334</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sittner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ben-Shmuel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Glinert</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bar-David</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Schlomovitz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kobiler</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Using old antibiotics to treat ancient bacterium-&#x003b2;-lactams for Bacillus anthracis meningitis.</article-title>
            <source>PLoS One</source>
            <year>2020</year>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>e0228917</fpage>
            <pub-id pub-id-type="pmid">32053632</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ai</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Research on degradation of penicillins in milk by &#x003b2;-lactamase using ultra-performance liquid chromatography coupled with time-of-flight mass spectrometry.</article-title>
            <source>J Dairy Sci</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>97</volume>
            <issue>7</issue>
            <fpage>4052</fpage>
            <page-range>4052-61</page-range>
            <pub-id pub-id-type="pmid">24792795</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soto</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Shoji</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Muto</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tomono</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Marshall</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Population pharmacokinetics of ampicillin and sulbactam in patients with community-acquired pneumonia: evaluation of the impact of renal impairment.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>77</volume>
            <issue>3</issue>
            <fpage>509</fpage>
            <page-range>509-21</page-range>
            <pub-id pub-id-type="pmid">24102758</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tamma</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Aitken</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Bonomo</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Mathers</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>van Duin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Clancy</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Infectious Diseases Society of America Guidance on the Treatment of AmpC &#x003b2;-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections.</article-title>
            <source>Clin Infect Dis</source>
            <year>2022</year>
            <month>Jul</month>
            <day>06</day>
            <volume>74</volume>
            <issue>12</issue>
            <fpage>2089</fpage>
            <page-range>2089-2114</page-range>
            <pub-id pub-id-type="pmid">34864936</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Campoli-Richards</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Brogden</surname>
                <given-names>RN</given-names>
              </name>
            </person-group>
            <article-title>Sulbactam/ampicillin. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use.</article-title>
            <source>Drugs</source>
            <year>1987</year>
            <month>Jun</month>
            <volume>33</volume>
            <issue>6</issue>
            <fpage>577</fpage>
            <page-range>577-609</page-range>
            <pub-id pub-id-type="pmid">3038500</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <collab>Committee on Practice Bulletins-Obstetrics</collab>
            <article-title>ACOG Practice Bulletin No. 199: Use of Prophylactic Antibiotics in Labor and Delivery.</article-title>
            <source>Obstet Gynecol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>132</volume>
            <issue>3</issue>
            <fpage>e103</fpage>
            <page-range>e103-e119</page-range>
            <pub-id pub-id-type="pmid">30134425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r24">
          <label>24</label>
          <element-citation publication-type="book">
            <chapter-title>Ampicillin and Sulbactam</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000042</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nahata</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Vashi</surname>
                <given-names>VI</given-names>
              </name>
              <name>
                <surname>Swanson</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Messig</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of ampicillin and sulbactam in pediatric patients.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>1999</year>
            <month>May</month>
            <volume>43</volume>
            <issue>5</issue>
            <fpage>1225</fpage>
            <page-range>1225-9</page-range>
            <pub-id pub-id-type="pmid">10223940</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gurvits</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Black hairy tongue syndrome.</article-title>
            <source>World J Gastroenterol</source>
            <year>2014</year>
            <month>Aug</month>
            <day>21</day>
            <volume>20</volume>
            <issue>31</issue>
            <fpage>10845</fpage>
            <page-range>10845-50</page-range>
            <pub-id pub-id-type="pmid">25152586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pumphrey</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cant</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Clarke</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Corbett</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dawson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ewan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fo&#x000eb;x</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gabbott</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Griffiths</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Harper</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Jewkes</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Maconochie</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nasser</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nolan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rylance</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sheikh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Unsworth</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Warrell</surname>
                <given-names>D</given-names>
              </name>
              <collab>Working Group of the Resuscitation Council (UK)</collab>
            </person-group>
            <article-title>Emergency treatment of anaphylactic reactions--guidelines for healthcare providers.</article-title>
            <source>Resuscitation</source>
            <year>2008</year>
            <month>May</month>
            <volume>77</volume>
            <issue>2</issue>
            <fpage>157</fpage>
            <page-range>157-69</page-range>
            <pub-id pub-id-type="pmid">18358585</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r28">
          <label>28</label>
          <element-citation publication-type="book">
            <chapter-title>Ampicillin</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2020</year>
            <month>10</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">31643230</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r29">
          <label>29</label>
          <element-citation publication-type="book">
            <chapter-title>Ampicillin-Sulbactam</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2020</year>
            <month>10</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">31643208</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hornik</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Benjamin</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Pencina</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Tremoulet</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Capparelli</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Ericson</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Cohen-Wolkowiez</surname>
                <given-names>M</given-names>
              </name>
              <collab>Best Pharmaceuticals for Children Act&#x02014;Pediatric Trials Network</collab>
            </person-group>
            <article-title>Electronic Health Records and Pharmacokinetic Modeling to Assess the Relationship between Ampicillin Exposure and Seizure Risk in Neonates.</article-title>
            <source>J Pediatr</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>178</volume>
            <fpage>125</fpage>
            <page-range>125-129.e1</page-range>
            <pub-id pub-id-type="pmid">27522443</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oldfield</surname>
                <given-names>EC</given-names>
              </name>
            </person-group>
            <article-title>Clostridium difficile-associated diarrhea: risk factors, diagnostic methods, and treatment.</article-title>
            <source>Rev Gastroenterol Disord</source>
            <year>2004</year>
            <season>Fall</season>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>186</fpage>
            <page-range>186-95</page-range>
            <pub-id pub-id-type="pmid">15580153</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Joung</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Seo</surname>
                <given-names>HK</given-names>
              </name>
            </person-group>
            <article-title>Association Between Antibiotic Treatment and the Efficacy of Intravesical BCG Therapy in Patients With High-Risk Non-Muscle Invasive Bladder Cancer.</article-title>
            <source>Front Oncol</source>
            <year>2021</year>
            <volume>11</volume>
            <fpage>570077</fpage>
            <pub-id pub-id-type="pmid">33868985</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheng</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Syu</surname>
                <given-names>FK</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Correlation between drug-drug interaction-induced Stevens-Johnson syndrome and related deaths in Taiwan.</article-title>
            <source>J Food Drug Anal</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>427</fpage>
            <page-range>427-432</page-range>
            <pub-id pub-id-type="pmid">28911598</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yeh</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Suppressive drug combinations and their potential to combat antibiotic resistance.</article-title>
            <source>J Antibiot (Tokyo)</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>70</volume>
            <issue>11</issue>
            <fpage>1033</fpage>
            <page-range>1033-1042</page-range>
            <pub-id pub-id-type="pmid">28874848</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dicks</surname>
                <given-names>LMT</given-names>
              </name>
              <name>
                <surname>Mikkelsen</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Brandsborg</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Marcotte</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Clostridium difficile, the Difficult "Kloster" Fuelled by Antibiotics.</article-title>
            <source>Curr Microbiol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>76</volume>
            <issue>6</issue>
            <fpage>774</fpage>
            <page-range>774-782</page-range>
            <pub-id pub-id-type="pmid">30084095</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ciccarese</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Trave</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Herzum</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Parodi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Drago</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Dermatological manifestations of Epstein-Barr virus systemic infection: a case report and literature review.</article-title>
            <source>Int J Dermatol</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>59</volume>
            <issue>10</issue>
            <fpage>1202</fpage>
            <page-range>1202-1209</page-range>
            <pub-id pub-id-type="pmid">32346863</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuruvilla</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Anaphylaxis to drugs.</article-title>
            <source>Immunol Allergy Clin North Am</source>
            <year>2015</year>
            <month>May</month>
            <volume>35</volume>
            <issue>2</issue>
            <fpage>303</fpage>
            <page-range>303-19</page-range>
            <pub-id pub-id-type="pmid">25841553</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ooi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Asai</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Risk evaluation of ampicillin/sulbactam-induced liver injury based on albumin-bilirubin score.</article-title>
            <source>J Infect Chemother</source>
            <year>2023</year>
            <month>Sep</month>
            <volume>29</volume>
            <issue>9</issue>
            <fpage>900</fpage>
            <page-range>900-904</page-range>
            <pub-id pub-id-type="pmid">37301371</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>King</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Kern</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Jaar</surname>
                <given-names>BG</given-names>
              </name>
            </person-group>
            <article-title>Extracorporeal Removal of Poisons and Toxins.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2019</year>
            <month>Sep</month>
            <day>06</day>
            <volume>14</volume>
            <issue>9</issue>
            <fpage>1408</fpage>
            <page-range>1408-1415</page-range>
            <pub-id pub-id-type="pmid">31439539</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hodgman</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dasta</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Visconti</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Reilley</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>Ampicillin-associated seizures.</article-title>
            <source>South Med J</source>
            <year>1984</year>
            <month>Oct</month>
            <volume>77</volume>
            <issue>10</issue>
            <fpage>1323</fpage>
            <page-range>1323-5</page-range>
            <pub-id pub-id-type="pmid">6484655</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barlam</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Cosgrove</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Abbo</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>MacDougall</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schuetz</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Septimus</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Srinivasan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dellit</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Falck-Ytter</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Fishman</surname>
                <given-names>NO</given-names>
              </name>
              <name>
                <surname>Hamilton</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Jenkins</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Lipsett</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Malani</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>May</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Moran</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Neuhauser</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Newland</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Ohl</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Samore</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Seo</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Trivedi</surname>
                <given-names>KK</given-names>
              </name>
            </person-group>
            <article-title>Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America.</article-title>
            <source>Clin Infect Dis</source>
            <year>2016</year>
            <month>May</month>
            <day>15</day>
            <volume>62</volume>
            <issue>10</issue>
            <fpage>e51</fpage>
            <page-range>e51-77</page-range>
            <pub-id pub-id-type="pmid">27080992</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burnham</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Olsen</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Stwalley</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kwon</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Babcock</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Kollef</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Infectious Diseases Consultation Reduces 30-Day and 1-Year All-Cause Mortality for Multidrug-Resistant Organism Infections.</article-title>
            <source>Open Forum Infect Dis</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>ofy026</fpage>
            <pub-id pub-id-type="pmid">29577058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37541.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Polat</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Koc</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Demirkan</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The role of the clinical pharmacist in the prevention of drug-induced acute kidney injury in the intensive care unit.</article-title>
            <source>J Clin Pharm Ther</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>47</volume>
            <issue>12</issue>
            <fpage>2287</fpage>
            <page-range>2287-2294</page-range>
            <pub-id pub-id-type="pmid">36394173</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
